Back to Search
Start Over
Long-term use of deferiprone significantly enhances left-ventricular ejection function in thalassemia major patients
- Source :
- American Journal of Hematology. 87:732-733
- Publication Year :
- 2012
- Publisher :
- Wiley, 2012.
-
Abstract
- A multicenter randomized open-label long-term sequential deferiprone–deferoxamine (DFP-DFO) versus DFP alone trial (sequential DFP-DFO) performed in patients with thalassemia major (TM) was retrospectively reanalyzed to assess the variation in the left ventricular ejection fraction (LVEF) [1].
- Subjects :
- Adult
Male
medicine.medical_specialty
Time Factors
Pyridones
Heart Ventricles
Thalassemia
Deferoxamine
Iron Chelating Agents
Models, Biological
Drug Administration Schedule
chemistry.chemical_compound
Internal medicine
Humans
Medicine
Left ventricular ejection
Deferiprone
In patient
Retrospective Studies
Ultrasonography
Ejection fraction
business.industry
beta-Thalassemia
Stroke Volume
Hematology
medicine.disease
humanities
chemistry
Cardiology
Drug Therapy, Combination
Female
Thalassemia major, Left ventricular ejection fraction, Deferiprone, sequential deferiprone-deferoxamine, Echocardiography, Chelation
business
Subjects
Details
- ISSN :
- 03618609
- Volume :
- 87
- Database :
- OpenAIRE
- Journal :
- American Journal of Hematology
- Accession number :
- edsair.doi.dedup.....4118cced90c1d8039af252c132a87f63
- Full Text :
- https://doi.org/10.1002/ajh.23219